New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition)

Guest Editors:

Dr. Luis Ibarra

Dr. Laura Natalia Milla Sanabria

Dr. Nuria Arias-Ramos

Deadline for manuscript submissions:
31 December 2024

Message from the Guest Editors

Brain malignancies pose a substantial obstacle for the field of oncology and the advancement of pharmaceuticals. Historically, the treatment of brain tumors has been challenging due to their physical and molecular characteristics. The tumor's exposure to systemic therapy may be diminished by the blood–tumor barrier, which may differ from the normal blood–brain barrier and frequently complicate complete surgery. Moreover, brain tumors possess microenvironmental characteristics that are remarkably distinct and intricately associated with developmental factors.

We declare a call for papers for the 2nd series of this Special Issue with great enthusiasm. This series demonstrates our dedication to collecting and presenting the most recent research, advancements and difficulties in brain tumors. This resource enhances the comprehension of various primary brain cancers by examining novel therapy approaches and targeted medications, while delving into the significance of brain tumors at the cellular and molecular levels. We are specifically seeking fresh viewpoints, approaches to unresolved issues and creative solutions that expand upon the research offered in the 1st series.

mdpi.com/si/197098

Special Issue

Editor-in-Chief

Prof. Dr. Stephen D. Meriney
Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, CAPlus / SciFinder, and other databases.
Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2023).

Contact Us